USCA RIA’s Novartis NVS Stock Holding History

USCA RIA’s Portfolio NVS Stock Details NVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	$8.25M	Buy	90,427 +1,716	+2%	+$153K	0.5%	50
2021 Q1	$7.58M	Buy	88,711 +8,478	+11%	+$761K	0.5%	51
2020 Q4	$7.58M	Buy	80,233 +702	+0.9%	+$61.3K	0.53%	38
2020 Q3	$6.92M	Sell	79,531 -3,226	-4%	-$279K	0.54%	38
2020 Q2	$7.23M	Buy	82,757 +10,198	+14%	+$880K	0.64%	32
2020 Q1	$5.98M	Buy	72,559 +5,074	+8%	+$453K	0.69%	30
2019 Q4	$6.39M	Sell	67,485 -9,926	-13%	-$891K	0.57%	48
2019 Q3	$6.73M	Sell	77,411 -6,665	-8%	-$598K	0.66%	42
2019 Q2	$7.68M	Buy	84,076 +9,970	+13%	+$844K	0.78%	33
2019 Q1	$6.38M	Buy	74,106 +16,904	+30%	+$1.36M	0.69%	40
2018 Q4	$4.4M	Buy	57,202 +20,069	+54%	+$1.56M	0.59%	46
2018 Q3	$2.87M	Sell	37,133 -3,299	-8%	-$244K	0.29%	109
2018 Q2	$2.74M	Buy	40,432 +3,978	+11%	+$275K	0.29%	105
2018 Q1	$2.64M	Buy	36,454 +7,906	+28%	+$602K	0.29%	106
2017 Q4	$2.15M	Buy	28,548 +4,754	+20%	+$359K	0.24%	121
2017 Q3	$1.78M	Hold	23,794	–	–	0.23%	132
2017 Q2	$1.78M	Buy	23,794 +6,904	+41%	+$489K	0.23%	133
2017 Q1	$1.12M	Sell	16,890 -1,618	-9%	-$108K	0.16%	174
2016 Q4	$1.21M	Buy	18,508 +4,397	+31%	+$285K	0.19%	151
2016 Q3	$998K	Buy	14,111 +1,627	+13%	+$119K	0.17%	159
2016 Q2	$923K	Buy	12,484 +3,324	+36%	+$230K	0.16%	167
2016 Q1	$595K	Buy	9,160 +2,242	+32%	+$153K	0.11%	188
2015 Q4	$533K	Buy	6,918 +1,196	+21%	+$95K	0.12%	190
2015 Q3	$471K	Buy	5,722 +57	+1%	+$5.07K	0.12%	191
2015 Q2	$499K	Buy	5,665 +837	+17%	+$76.8K	0.13%	175
2015 Q1	$427K	Buy	4,828 +129	+3%	+$11.4K	0.11%	201
2014 Q4	$390K	Buy	4,699 +186	+4%	+$15.4K	0.11%	212
2014 Q3	$381K	Buy	4,513 +1,383	+44%	+$112K	0.12%	198
2014 Q2	$254K	Buy	+3,130	New	+$246K	0.09%	242

Other funds holding NVS

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Aristotle Capital Management Los Angeles, California $47.8B AUM 13.38% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

USCA RIA's NVS Position: Q2 2021 in Review

USCA RIA increased its Novartis (NVS) stake by 1.9% in Q2 2021, buying an estimated $153K and bringing the position to 90,427 shares worth $8.25M. The position accounts for 0.5% of the portfolio, ranked #50.

USCA RIA first reported a position in NVS in Q2 2014 and has held it in 29 quarters since. 1,119 funds tracked by Wall St. Rank hold NVS as of Q2 2021.

USCA RIA held 90,427 shares of Novartis worth $8.25M as of Q2 2021.
USCA RIA bought 1,716 Novartis shares in Q2 2021, an estimated $153K.
Novartis made up 0.5% of USCA RIA's portfolio in Q2 2021, its #50 holding.
USCA RIA first reported a position in Novartis in Q2 2014 and has held it in 29 quarters since.
1,119 funds tracked by Wall St. Rank held Novartis as of Q2 2021.

Based on USCA RIA's 13F filing for Q2 2021, filed 28 Jul 2021.